INTERSECT ENT INC (XENT) Stock Price, Forecast & Analysis
NASDAQ:XENT • US46071F1030
XENT Key Statistics, Chart & Performance
The current stock price of XENT is 28.24 null. In the past month the price increased by 0.89%. In the past year, price increased by 59.91%.
XENT Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to XENT. When comparing the yearly performance of all stocks, XENT is one of the better performing stocks in the market, outperforming 96.39% of all stocks.
XENT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XENT. Both the profitability and financial health of XENT have multiple concerns.
XENT Financial Highlights
Over the last trailing twelve months XENT reported a non-GAAP Earnings per Share(EPS) of -5.03. The EPS decreased by -120.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -161.94% | ||
| ROA | -132.19% | ||
| ROE | N/A | ||
| Debt/Equity | -1.52 |
XENT Forecast & Estimates
7 analysts have analysed XENT and the average price target is 28.82 null. This implies a price increase of 2.04% is expected in the next year compared to the current price of 28.24.
For the next year, analysts expect an EPS growth of 37% and a revenue growth 14.26% for XENT
XENT Ownership
XENT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 20.26 | 202.318B | ||
| ISRG | INTUITIVE SURGICAL INC | 49.26 | 178.812B | ||
| SYK | STRYKER CORP | 25.62 | 148.172B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.94 | 113.97B | ||
| IDXX | IDEXX LABORATORIES INC | 44.32 | 52.44B | ||
| BDX | BECTON DICKINSON AND CO | 11.2 | 50.281B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.08 | 50.178B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.78 | 38.406B | ||
| RMD | RESMED INC | 20.87 | 37.332B | ||
| DXCM | DEXCOM INC | 29.08 | 28.639B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About XENT
Company Profile
Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. The company is headquartered in Menlo Park, California and currently employs 433 full-time employees. The company went IPO on 2014-07-24. The firm's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company also offers ENT products, such as VenSure and CUBE.
Company Info
INTERSECT ENT INC
1555 Adams Dr
Menlo Park CALIFORNIA 94025 US
CEO: Thomas A. West
Employees: 433
Phone: 16506412100.0
INTERSECT ENT INC / XENT FAQ
Can you describe the business of INTERSECT ENT INC?
Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. The company is headquartered in Menlo Park, California and currently employs 433 full-time employees. The company went IPO on 2014-07-24. The firm's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company also offers ENT products, such as VenSure and CUBE.
What is the current price of XENT stock?
The current stock price of XENT is 28.24 null.
Does INTERSECT ENT INC pay dividends?
XENT does not pay a dividend.
How is the ChartMill rating for INTERSECT ENT INC?
XENT has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for INTERSECT ENT INC?
INTERSECT ENT INC (XENT) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
What is INTERSECT ENT INC worth?
INTERSECT ENT INC (XENT) has a market capitalization of 954.79M null. This makes XENT a Small Cap stock.